Last reviewed · How we verify

NCT02265094: MEM-TA

Associative Memory in Autism Spectrum Disorder

Completed NA Last updated 5 March 2026
What this trial tests

NA trial testing Electroencephalography in Autistic Disorder in 80 participants. Completed in 8 December 2021.

Timeline
22 December 2015
Primary endpoint
8 December 2020
8 December 2021

Quick facts

Lead sponsorUniversity Hospital, Caen
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designfactorial
Maskingnone
Primary purposebasic science
Enrollment80
Start date22 December 2015
Primary completion8 December 2020
Estimated completion8 December 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Caen

Who can join

Adults 10 to 18, any sex, with Autistic Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the neural substrates of associative memory in Autism Spectrum Disorder using both behavioural and EEG assessments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Electroencephalography

Trials testing the same drug.

Other recruiting trials for Autistic Disorder

Currently open trials in the same condition.

Other University Hospital, Caen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02265094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing